The global neurological biomarkers market is witnessing prominent growth. Increasing investment, prevalence of neurological disorders, and rising awareness are the key growth contributors. The neurological biomarkers are present in the cerebral spinal fluid (CSF) and in very small quantities in the blood. This makes it difficult to detect and identify the natural biomarkers present in the blood. The neurological biomarkers in the cerebral spinal fluid (CSF) are inaccessible without invasive surgical method. However, advancement in technology has enabled the monitoring of biomarkers clusters or biomarker signatures in the blood cells. This has contributed towards the growth of neurological biomarkers market. Moreover, the neurological biomarkers facilitate early detection and monitoring of neurological disorders and thus are gaining wide acceptance worldwide.
North America contributed the largest share to the global neurological biomarkers market in 2019 owing to focused research and development activities on neurological diagnostic procedures and therapeutics. Prevalence and growth of neurological disorders in the United States, and increasing awareness are the prime factors high demand for neurological biomarkers in North America. The Asia Pacific countries such as China, India, and Japan are investing significantly in research and development of advanced therapeutics and clinical diagnostics focused on neurological disorders. The Asia Pacific neurological biomarker market is anticipated to be the most lucrative market during the forecast period.
The report titled “Neurological Biomarkers Market - Global Market Share, Trends, Analysis and Forecasts, 2022-2032” wherein 2020 is historic period, 2021 is the base year, and 2022 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global neurological biomarkers market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market. For instance, Thermo Fisher Scientific Inc. reported revenues of US$ 24.4 billion in 2018 and the product segment analysis of the company indicates that Laboratory Products & Services business segment of the company dominated revenue in 2018.
The global neurological biomarkers market is segmented based on type, disease type, application, end user, and geography. Based on type, the global neurological biomarkers market is segmented into genomic, proteomic, metabolomic, imaging, and others. Based on disease type, the global neurological biomarkers market is segmented into Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, autism spectrum disorders, and others. Based on application, the global neurological biomarkers market is segmented into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other. Based on end user, the global neurological biomarkers market is segmented into hospital, clinical diagnostic centers, research organizations, and others. Based on geography, the global neurological biomarkers market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
The research would provide in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment, and would identify the segment of the company focusing on neurological biomarker, products and technology. Market share of prominent companies in the global neurological biomarker market would be included. For instance, Thermo Fisher Scientific Inc. operates through four business segments namely Life Sciences Solutions, Laboratory Products & Services, Specialty Diagnostics, and Analytical Instruments. The neurological biomarkers products and technology is delivered under Life Sciences Solutions business segment of the company with revenue contribution of US$ 6.1 billion in 2018.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the neurological biomarker companies. Furthermore, the global neurological biomarkers market study would take into consideration the participants engaged throughout the ecosystem of the market, along with their contribution. Product portfolio would focus on all the products under the neurological biomarkers business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global neurological biomarkers market.
Major players active in the global neurological biomarkers market include AbaStar MDx, Inc., Abbott Laboratories, Acumen Pharmaceuticals, Inc., Alseres Pharmaceuticals, Inc., Athena Diagnostics, BANYAN BIOMARKERS, INC., Bio-Rad Laboratories, Inc., Myriad RBM, Inc., QIAGEN, and Thermo Fisher Scientific Inc.
InsightSLICE adopts a research methodology which is highly meticulous and comprehensive, yielding accurate research results. Our research methodology utilizes data triangulation model which helps in the precise collection and validation of information. Our set processes for problem solving and paid primary tools guarantee that any client requirement is met with utmost diligence and accuracy. Some of the primary components that are consequential to our research approach are:
Secondary Research or Desk Research
Distinctive Data Model
Secondary Sources include but are not limited to:
Past Published Research
Historical Data and Information
Primary Sources include but are not limited to:
InsightSLICE also leverages three types of data triangulation approaches as follows:
Data Source Triangulation
Extracting data and validation from multiple type of secondary and primary sources
Combining various methodologies to validate data inputs
Applying different theories to check credibility of data sets
North America contributed the largest share to the global neurological biomarkers market owing to focused research and development activities on neurological diagnostic procedures and therapeutics. Prevalence and growth of neurological disorders in the United States, and increasing awareness are the prime factors high demand for neurological biomarkers in North America.